Next Article in Journal
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2011, 4(8), 1088-1100; doi:10.3390/ph4081088
Review

Beta-Blockers and Oxidative Stress in Patients with Heart Failure

1,* , 1, 1, 1, 1, 1, 1, 1, 2, 1, 1, 1, 1, 1, 2, 3, 1, 1 and 1
Received: 12 July 2011; Accepted: 28 July 2011 / Published: 5 August 2011
(This article belongs to the Special Issue Betablockers)
View Full-Text   |   Download PDF [1912 KB, uploaded 5 August 2011]   |   Browse Figures
Abstract: Oxidative stress has been implicated in the pathogenesis of heart failure. Reactive oxygen species (ROS) are produced in the failing myocardium, and ROS cause hypertrophy, apoptosis/cell death and intracellular Ca2+ overload in cardiac myocytes. ROS also cause damage to lipid cell membranes in the process of lipid peroxidation. In this process, several aldehydes, including 4-hydroxy-2-nonenal (HNE), are generated and the amount of HNE is increased in the human failing myocardium. HNE exacerbates the formation of ROS, especially H2O2 and ·OH, in cardiomyocytes and subsequently ROS cause intracellular Ca2+ overload. Treatment with beta-blockers such as metoprolol, carvedilol and bisoprolol reduces the levels of oxidative stress, together with amelioration of heart failure. This reduction could be caused by several possible mechanisms. First, the beta-blocking effect is important, because catecholamines such as isoproterenol and norepinephrine induce oxidative stress in the myocardium. Second, anti-ischemic effects and negative chronotropic effects are also important. Furthermore, direct antioxidative effects of carvedilol contribute to the reduction of oxidative stress. Carvedilol inhibited HNE-induced intracellular Ca2+ overload. Beta-blocker therapy is a useful antioxidative therapy in patients with heart failure.
Keywords: beta-blocker; oxidative stress; heart failure beta-blocker; oxidative stress; heart failure
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Nakamura, K.; Murakami, M.; Miura, D.; Yunoki, K.; Enko, K.; Tanaka, M.; Saito, Y.; Nishii, N.; Miyoshi, T.; Yoshida, M.; Oe, H.; Toh, N.; Nagase, S.; Kohno, K.; Morita, H.; Matsubara, H.; Kusano, K.F.; Ohe, T.; Ito, H. Beta-Blockers and Oxidative Stress in Patients with Heart Failure. Pharmaceuticals 2011, 4, 1088-1100.

AMA Style

Nakamura K, Murakami M, Miura D, Yunoki K, Enko K, Tanaka M, Saito Y, Nishii N, Miyoshi T, Yoshida M, Oe H, Toh N, Nagase S, Kohno K, Morita H, Matsubara H, Kusano KF, Ohe T, Ito H. Beta-Blockers and Oxidative Stress in Patients with Heart Failure. Pharmaceuticals. 2011; 4(8):1088-1100.

Chicago/Turabian Style

Nakamura, Kazufumi; Murakami, Masato; Miura, Daiji; Yunoki, Kei; Enko, Kenki; Tanaka, Masamichi; Saito, Yukihiro; Nishii, Nobuhiro; Miyoshi, Toru; Yoshida, Masashi; Oe, Hiroki; Toh, Norihisa; Nagase, Satoshi; Kohno, Kunihisa; Morita, Hiroshi; Matsubara, Hiromi; Kusano, Kengo F; Ohe, Tohru; Ito, Hiroshi. 2011. "Beta-Blockers and Oxidative Stress in Patients with Heart Failure." Pharmaceuticals 4, no. 8: 1088-1100.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert